The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
SAE is already in discussions, alongside its project partners, to find further locations to deploy the technology and fuel.
2:1 Nasdaq all good
https://simecatlantis.***/exhibition/
Website explains so much..........
https://www.ntu.ac.uk/__data/assets/image/0013/1213015/Mask-v2-for-web.jpg
fromBy Julia Bradshaw 15 December 2020 • 6:00am
AstraZeneca’s $39bn (£31bn) bid for US rare disease specialist Alexion has fired the starting gun on what could be a wave of deal-making in the pharmaceutical sector next year.
Analysts and investors predict 2021 will see a rebound in deals, stock market flotations and partnerships as investors look for the sort of long-term, stable returns that the pharmaceutical sector can offer and big pharma look to beef up their pipelines while borrowing remains cheap.
“I think there is a lot of capital washing around looking for a home,” said John Rountree, a partner at Novasecta.
“This will trigger M&A or partnerships, or IPOs or new companies. Investors should be bullish about the industry and the flow of capital towards pharma and biotech.
"There is some amazing science going on and everyone is confident that will be rewarded as the burden of disease is huge, there is still a huge amount of unmet need out there and the innovators in the industry will be rewarded.”
AstraZeneca will borrow heavily to fund the cash-and-shares bid that values Alexion’s shares at $175 - a 45pc premium to their Friday closing price before the deal was announced on Saturday.
For AstraZeneca, the deal will immediately boost profits and propel it securely at the top of the FTSE 100, supplanting banks, oil and big tobacco that have historically been the UK's most valuable companies.
“Since 1984 it has always been oil and banking and now Astra is at the top, and this marks a complete turnaround in fortunes both for AstraZeneca, but also for the sector,” said Ketan Patel of EdenTree Investment Management.
“I would expect to see a lot more of these deals and increased appetite among large pharmaceutical companies to buy in the ‘research’ part of research and development. The industry has not cut a dividend in 20 years, apart from in instances of M&A, so you are getting yield and growth from the sector. That is better than tobacco and oil.”
Mr Patel expected big pharma companies will seek to buy specialist players to fill their drug pipelines.
“Just look at the vaccine space around Covid,” he said. “Pfizer’s vaccine came from Biontech, Astra’s was spun out of Oxford. It is not inconceivable that smaller, yet still large, biopharmas like these will be in play.”
In Mr Patel's view, US firms Gilead and Amgen are potential targets because of their billions in annual sales, generous dividend yields and relatively cheap share prices.
“Companies can borrow cheaply and improve their profits and cash flow massively and gain exposure to cutting-edge technology, so I would expect to see a lot more of this,” he added. “The pandemic has shown drugs can be developed rapidly and successfully and gives pharma massive firepower.”
The deal comes as a report from Jefferies shows almost two thirds of senior healthcare executives expect M&A activity to increase next year. The survey of more than 500 people suggests.
I always invest then view in 6 months and 12 months. After consideration of developments here I still see Short Term 6 months upside and 12 months a well established business model. Director selling a bit of a shock but if you had been over the years ups and downs then business reality is a profit is considerable and still have share options to buy, so personal circumstances may have been reason.
Gareth seems an honest guy but the rules dictate ,it just means being mindful of openness. but do not stop comms with shareholders I email many holders and CEOs and ask for updates and with in guidelines they are very proactive in responses,as we all want the same thing the company to do well.
SP to me short term .20p and long term .50p unless we do a share consolidation as some companies do.
All in my honest opinion.
You must believe in the product or products to invest but also the person who leads, and I have sold half my holding to diverse into products and people I believe in. Business is business and no emotion should be attached but unfortunately as humans we do have emotions of trust and integrity. ~In twelve months time I may regret half of what I have done but feel better with this position at the moment.
The only reason for the disappointment is the integrity of portraying a timeline and perspective that the parameters of a saliva test to be nearer than it actually is, challenges yes, but surely the vision that was promoted and for all of us to be able to lead a normalise sort of life with a 5 minute test . I presume that seems to be challenging, what a shame.